Premium
Glutathione‐S‐Transferase π Expression in Transitional Cell Carcinoma of the Bladder
Author(s) -
THOMAS D. J.,
BIRCH P. J.,
VICKERS J.,
ROBINSON M.,
CLIFFORD S.,
HALL A.,
NEAL D. E.
Publication year - 1993
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1993.tb16259.x
Subject(s) - urothelium , staining , pathology , immunohistochemistry , transitional cell carcinoma , carcinoma , biology , carcinoma in situ , chemotherapy , cancer research , urinary bladder , bladder cancer , medicine , cancer , genetics
Summary Glutathione‐S‐transferase π (GSTπ) is a multifunctional protein that acts as an enzyme, involved in the detoxification of drugs and carcinogens. It has been implicated both in drug resistance and malignant transformation of epithelium. Using an indirect immunohistochemical technique, we have evaluated cytoplasmic and nuclear staining in normal urothelium, 23 superficial bladder tumours and 26 invasive tumours. All 26 invasive tumours had been treated with platinum‐based chemotherapy. Cytoplasmic staining was seen in normal urothelium and all bladder tumours. Nuclear staining was seen in 1 superficial tumour and in 13 invasive tumours. There was no association between nuclear staining and response to chemotherapy. Nuclear staining was seen in 1 area of dysplasia and in 2 of 3 areas of carcinoma in situ. GSTπ expression is not a predictor of response to chemotherapy. Increased intra‐nuclear expression of GSTπ may be associated with progression of transitional cell carcinoma of the bladder.